论文部分内容阅读
当前2型糖尿病治疗手段面临血糖控制不理想,现有方案很难从根本上改善β细胞功能、降低药物可引起体重增加和低血糖等不良作用,患者同时丰收在肥胖和高血压等心脑血管病高危因素等“多种挑战”。在这种背景下,人们普遍开始关注新型肠促胰素类药物。人胰升糖素样肽-1类似物利拉鲁肽具有促进胰岛素的合成和分泌、保护β细胞减少低血糖、减少食物摄取、延缓胃排空、减轻体重、降低收缩压和改善心脑血管疾病危险因素等生理作用。
The current treatment of type 2 diabetes is not ideal for the control of blood glucose, the existing program is difficult to fundamentally improve the function of β-cell, reduce the drug can cause weight gain and hypoglycemia and other adverse effects, while patients bumper in obesity and hypertension cardiovascular and other cardiovascular Risk factors such as “a variety of challenges ”. In this context, people generally begin to pay attention to the new type of incretin drugs. The human glucagon-like peptide-1 analog liraglutide promotes insulin synthesis and secretion, protects the β-cell from hypoglycemia, reduces food intake, delays gastric emptying, reduces body weight, reduces systolic pressure, and improves cardiovascular and cerebrovascular Disease risk factors and other physiological effects.